BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu Sells 49,858 Shares

Key Points

• Xiaobin Wu, COO of BeOne Medicines Ltd., sold 49,858 shares at an average price of $304.16, totaling approximately $15.16 million in the transaction.
• BeOne Medicines' stock has seen a recent uptick, trading up 3.8% to $321.36, with an average price target set by analysts at $330.89.
• The company reported $1.32 billion in revenue for the last quarter, significantly beating analyst estimates and showcasing its strong performance in the oncology sector.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) COO Xiaobin Wu sold 49,858 shares of BeOne Medicines stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $304.16, for a total transaction of $15,164,809.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Xiaobin Wu also recently made the following trade(s):

• On Thursday, August 14th, Xiaobin Wu sold 39,936 shares of BeOne Medicines stock. The stock was sold at an average price of $305.06, for a total transaction of $12,182,876.16.
• On Monday, June 23rd, Xiaobin Wu sold 1,363 shares of BeOne Medicines stock. The stock was sold at an average price of $260.00, for a total transaction of $354,380.00.
• On Tuesday, June 17th, Xiaobin Wu sold 630 shares of BeOne Medicines stock. The shares were sold at an average price of $250.87, for a total transaction of $158,048.10.
• On Monday, June 16th, Xiaobin Wu sold 1,543 shares of BeOne Medicines stock. The shares were sold at an average price of $265.52, for a total transaction of $409,697.36.
• On Friday, June 6th, Xiaobin Wu sold 1,934 shares of BeOne Medicines stock. The stock was sold at an average price of $253.15, for a total transaction of $489,592.10.

BeOne Medicines Trading Up 3.8%

NASDAQ ONC traded up $11.67 on Friday, hitting $321.36. 448,792 shares of the company were exchanged, compared to its average volume of 437,341. The stock has a market capitalization of $35.22 billion, a P/E ratio of -185.76 and a beta of 0.27. BeOne Medicines Ltd. - Sponsored ADR has a 12 month low of $170.99 and a 12 month high of $321.69. The stock's fifty day moving average is $274.62. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.72 and a current ratio of 1.95.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.84 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.36. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. The firm had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.24 billion. On average, analysts expect that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.

Analysts Set New Price Targets

ONC has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of BeOne Medicines from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Guggenheim upped their price target on shares of BeOne Medicines from $350.00 to $365.00 and gave the company a "buy" rating in a research note on Thursday, August 7th. TD Securities reiterated a "buy" rating and issued a $334.00 price target on shares of BeOne Medicines in a research note on Thursday, April 24th. Royal Bank Of Canada upped their price target on shares of BeOne Medicines from $349.00 to $364.00 and gave the company an "outperform" rating in a research note on Thursday, August 7th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of BeOne Medicines from $321.00 to $345.00 and gave the company an "overweight" rating in a report on Thursday, July 17th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $330.89.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd purchased a new stake in BeOne Medicines during the second quarter worth about $28,000. Daiwa Securities Group Inc. purchased a new position in shares of BeOne Medicines in the second quarter worth about $35,000. Farther Finance Advisors LLC purchased a new position in shares of BeOne Medicines in the second quarter worth about $39,000. Signaturefd LLC purchased a new position in shares of BeOne Medicines in the second quarter worth about $49,000. Finally, Parallel Advisors LLC purchased a new position in shares of BeOne Medicines in the second quarter worth about $59,000. 48.55% of the stock is owned by institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.